Our Innovation – Novel & Attractive vaccine candidates
Derived from a proven, state-of-the-art vaccine technology platform, our vaccines are highly innovative and address a high unmet medical need. With vaccines against against Dengue Virus, Yellow fever and the Chikungunya Virus we are initially we are concentrating on three candidates which we aim to develop up to proof-of-concept, with the first vaccine entering clinical trials in 2012.
- Series A Finance Round closed - 5 Mio. Euro for further product developmentmore
- Come and meet us! @ the Phacilitate Vaccine Forum, May 11-13, Barcelonamore
- R&D alliance with Institut Pasteur Themis and Institut Pasteur join forces to fight tropical infectious diseasesmore
- New Labs and Offices: Themis Bioscience moves to TZM Muthgassemore